Genetic liability to rheumatoid arthritis in relation to coronary artery disease and stroke risk.
MetadataShow full item record
Yuan, S., Carter, P., Mason, A., Yang, F., Burgess, S., & Larsson, S. C. (2022). Genetic liability to rheumatoid arthritis in relation to coronary artery disease and stroke risk.. Arthritis Rheumatol https://doi.org/10.1002/art.42239
OBJECTIVES: To assess the causality of the associations of rheumatoid arthritis (RA) with coronary artery disease (CAD) and stroke using Mendelian randomization approach. METHODS: Independent single nucleotide polymorphisms strongly associated with RA (n=70) were selected as instrumental variables from a genome-wide association meta-analysis including 14,361 RA cases and 43,923 controls of European ancestry. Summary-level data for CAD, all stroke, any ischemic stroke and its subtypes, intracerebral hemorrhage, and subarachnoid hemorrhage were obtained from meta-analyses of genetic studies, international genetic consortia, the UK Biobank, and the FinnGen consortium. We obtained summary-level data for common cardiovascular risk factors and related inflammatory biomarkers to assess possible mechanisms. RESULTS: Genetic liability to RA was associated with an increased risk of CAD and intracerebral hemorrhage. For one unit increase in log odds of RA, the combined odds ratios were 1.02 (95% confidence interval, 1.01, 1.03; p=0.003) for CAD and 1.05 (95% confidence interval, 1.02, 1.08; p=0.001) for intracerebral hemorrhage. Genetic liability to RA was associated increased levels of tumor necrosis factor and C-reactive protein (CRP). The association for CAD attenuated after adjustment for genetically predicted CRP levels. There were no associations of genetic liability to RA with the other studied outcomes. CONCLUSION: This study found that genetic liability to RA was associated with increased risk of CAD and intracerebral hemorrhage and that the association for CAD might be mediated by CRP. The heightened cardiovascular risk should be actively monitored and managed in RA patients, and this may include damping systemic inflammation.
Wellcome Trust (204623/Z/16/Z)
Embargo Lift Date
External DOI: https://doi.org/10.1002/art.42239
This record's URL: https://www.repository.cam.ac.uk/handle/1810/337055
All Rights Reserved
Licence URL: http://www.rioxx.net/licenses/all-rights-reserved